Randomised clinical trial: once- vs. twice-daily prolonged-release mesalazine for active ulcerative colitis.

When combined with mesalazine enema, prolonged-release mesalazineonce-daily 4 g is as effective and well tolerated as 2 g twice-daily for inducing remission in patients with mild-to-moderately active ulcerative colitis(Clinicaltrials.gov: NCT00737789).